| DC11823 |
BMS-929075 |
A highly potent, selective, orally bioavailable HCV NS5B polymerase inhibitor with IC50 of 9, 4, and 18 nM for GT1a, GT1b, and GT1b-C316N mutant in HCV replicon assay, respectively. |
|
| DC11825 |
MK-8876 |
A novel, broadly acting non-nucleoside inhibitor of HCV NS5B polymerase with IC50 of 3 nM and 2 nM for GT1b and GT2a, respectively. |
|
| DC11731 |
Ruzasvir |
A potent, pan-genotype HCV NS5A inhibitor with replicon EC90 of 0.003, 0.016, 0.067, 0.036, 0.007, and 0.007 nM for GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a, and Gt4a, respectively.. |
|
| DC7541 |
Balapiravir |
Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). |
|
| DC5077 |
Boceprevir(EBP 520; SCH 503034 )
Featured
|
Boceprevir(EBP 520; SCH 503034 ) is useful for Anti HCV. |
|
| DC11081 |
Coblopasvir |
Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection.. |
|
| DC11214 |
Cyclophilin inhibitor C31 |
Cyclophilin inhibitor C31 (SMCypI C31) is a small-molecule cyclophilin (CypA) inhibitor (SMCypI) with PPIase inhibition IC50 of 0.1 uM, displays anti-HCV activity (HCV Gt1b replicon EC50=0.4 uM) and disrupts the CypA-NS5A interaction. |
|
| DC7394 |
Daclatasvir dihydrochloride (BMS-790052)
Featured
|
Daclatasvir (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. |
|
| DC8238 |
Danoprevir
Featured
|
Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. |
|
| DC10818 |
ABT-493(Glecaprevir)
Featured
|
Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. |
|
| DC11494 |
INX-08189 |
INX-08189 is a phosphoramidate prodrug of O-6-methyl-2-C-methyl guanosine, potent inhibitor of HCV NS5B polymerase with IC50 of 10 nM in replicon assay. |
|
| DC8178 |
Beclabuvir(BMS-791325) |
non-nucleoside inhibitor of the NS5B |
|
| DC8183 |
Paritaprevir(Veruprevir ABT-450)
Featured
|
NS3/4A protease inhibitor |
|
| DC10728 |
Pibrentasvir(ABT-530)
Featured
|
Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6. |
|
| DC4121 |
PSI6130
Featured
|
PSI-6130(R 1656) is a Hepatitis C Virus Nucleoside Inhibitor. PSI-6130(R 1656) is useful for Antiviral agents. |
|
| DC9462 |
R-7128(Mericitabine)
Featured
|
R-7128(Mericitabine) is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, with activity across all HCV genotypes.
|
|
| DC8190 |
Ravidasvir hydrochloride (PPI-668)
Featured
|
Ravidasvir(PPI-668) is a NS5A Inhibitor. |
|
| DC8612 |
Simeprevir(TMC-435) |
Simeprevir (TMC 435350) is a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM). |
|
| DC9463 |
Tegobuvir (GS-9190; GS 333126)
Featured
|
Tegobuvir (GS-9190; GS 333126) is a non-nucleoside nonstructural protein (NS)5B polymerase inhibitor.
|
|
| DC1008 |
Telaprevir (VX-950)
Featured
|
Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM. |
|
| DC10104 |
VX222(Lomibuvir)
Featured
|
VCH-222(Lomibuvir) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. |
|
| DC9751 |
Velpatasvir(GS5816)
Featured
|
Velpatasvir(GS-5816) is a potent and selective Hepatitis C virus NS5A inhibitor. |
|
| DC28522 |
BI-1230 |
BI-1230 is potent and digit nanomolar inhibitor of HCV NS3 protease and of viral replication. BI-1230 is also highly selective against other serine/cysteine proteases. BI-1230 shows good Pharmacokinetic(PK) activity. |
|
| DC28706 |
HCV-IN-7 |
HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC50s of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 has anti-viral activity. |
|
| DC28707 |
HCV-IN-7 hydrochloride |
HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC50s of 3-47 pM. HCV-IN-7 hydrochloride shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 hydrochloride has anti-viral activity. |
|
| DC40585 |
Monodes(N-carboxymethyl)valine Daclatasvir |
Monodes(N-carboxymethyl)valine Daclatasvir (Daclatasvir Impurity A) is the main degradation product of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor. |
|
| DC41367 |
γ-Fagarine |
γ-Fagarine is a furoquinoline alkaloid naturally occurring in Rutae Herba. γ-Fagarine has strong anti-HCV activities with IC50 of 20.4 μg/mL and is also a sister chromatid exchanges (SCEs) inducer. |
|
| DC41459 |
Isoeuphorbetin |
Isoeuphorbetin, a dimeric coumarin isolated from Viola philippica, is a potent HCV protease inhibitor with an IC50 of 3.63 μg/mL. |
|
| DC42004 |
Hepatitis Virus C NS3 Protease Inhibitor 2 |
Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of hepatitis C virus (HCV) NS3 protease, with a Ki of 41 nM. |
|
| DC42272 |
SMCypI C31 |
SMCypI C31 is a non-peptidic cyclophilin with potent peptidyl-prolyl cis/trans isomerases (PPIase)y activity (IC50 of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC50s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction. |
|
